One study analysed the prevalence of PDGFRA mutations in patients enrolled in a phase I/II study of imatinib mesylate in recurrent malignant gliomas; however, no activating mutations were observed (Wen et al, 2006). This evidence concerns the gene PDGFRA and malignant glioma.